SCHEMBL673750

SCHEMBL673750

O=C(O)CC(=O)OC(CC(=O)O)(CC(=O)O)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.37
TSHR P16473 2/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
ACLY P53396 3/20 0.35
LDHA P00338 1/20 0.35
SRR Q9GZT4 1/20 0.35
HMGCR P04035 1/20 0.32
CHRM1 P11229 1/20 0.32
TBXA2R P21731 1/20 0.32
ADRA1A P35348 1/20 0.32
CPT2 P23786 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8741818 0.93 ALDH1A1 (0.39) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL16393918 0.91 ALDH1A1 (0.37) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL304602 0.85 MGAM (0.43) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL1989298 0.84 ALDH1A1 (0.39) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL10410369 0.82 TSHR (0.41) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL27076088 0.82 ALDH1A1 (0.37) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL28452924 0.82 ALDH1A1 (0.37) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL9418856 0.80 TSHR (0.38) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
SCHEMBL11245866 0.80 ALDH1A1 (0.36) ALDH1A1TSHRCYP2D6CYP2C19HIF1A
Succinic Acid SCHEMBL8002651 0.80 EGLN1 (0.39) ALDH1A1TSHRCYP2D6CYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101657209-B Composition for preventing and treating periodontitis comprising extract of rehmanniae radix preparata, notoginseng radix or mixture thereof as effective ingredient OSCOTEC INC 2014-01-01 CN disclosed
US-8333998-B2 enhances the expression of osteoprotegerin (OPG) in osteoblasts and effectively inhibits the generation and activation of osteoclasts OSCOTEC INC. (KR) 2012-12-18 US disclosed
CN-101119737-B A herbal mixture extract of pleurotus eryngii, acanthopanacis cortex and notoginseng radix and a composition comprising the same for prevention and treatment of periodontitis OSCOTEC INC 2012-11-28 CN disclosed
US-8227456-B2 Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-07-24 US disclosed
EP-1784173-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES KOREA RES INST CHEM TECH (KR) 2012-01-18 EP disclosed
US-8053001-B2 enhances the expression of osteoprotegerin (OPG) in osteoblasts and effectively inhibits the generation and activation of osteoclasts OSCOTEC INC. (KR) 2011-11-08 US disclosed
CN-101128210-B A herbal mixture extract of rehmanniae radix preparata and acanthopanacis cortex and a composition comprising the same for prevention and treatment of osteoporosis OSCOTEC INC 2011-09-07 CN disclosed
US-7879835-B2 treating osteoporosis, comprising administering drugs such as (E)-methyl 2-(2-((4-octylphenoxy)methyl)-3-methoxyacrylate, which inhibit osteoclast formation or resorption activity; side effect reduction KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-02-01 US disclosed
US-20100256367-A1 Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-10-07 US disclosed
US-7794760-B2 Herbal mixture extract of Pleurotus eryngii, Acanthopanacis Cortex and Notoginseng Radix and a composition comprising the same for prevention and treatment of periodontitis OSCOTEC INC. (KR) 2010-09-14 US disclosed
EP-1848450-A1 A HERBAL MIXTURE EXTRACT OF PLEUROTUS ERYNGII, ACANTHOPANACIS CORTEX AND NOTOGINSENG RADIX AND A COMPOSITION COMPRISING THE SAME FOR PREVENTION AND TREATMENT OF PERIODONTITIS Oscotec Inc. (KR) 2007-10-31 EP disclosed
EP-1784173-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES Korea Research Institute of Chemical Technology (KR) 2007-05-16 EP disclosed
WO-2006091030-A1 A HERBAL MIXTURE EXTRACT OF REHMANNIAE RADIX PREPARATA AND ACANTHOPANACIS CORTEX AND A COMPOSITION COMPRISING THE SAME FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS OSCOTEC INC. (KR) 2006-08-31 WO disclosed
WO-2006088324-A1 A HERBAL MIXTURE EXTRACT OF PLEUROTUS ERYNGII, ACANTHOPANACIS CORTEX AND NOTOGINSENG RADIX AND A COMPOSITION COMPRISING THE SAME FOR PREVENTION AND TREATMENT OF PERIODONTITIS OSCOTEC INC. (KR) 2006-08-24 WO disclosed
US-20060004088-A1 Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same OCT INC. (KR) 2006-01-05 US disclosed
WO-2005123054-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2005-12-29 WO disclosed
WO-2004037804-A1 FURAN DERIVATIVES FOR PREVENTING AND CURING OSTEOPOROSIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME OSCOTEC INC. (KR) 2004-05-06 WO disclosed
EP-0785800-A1 PROBIOTIC FOR CONTROL OF $i(SALMONELLA) THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Agriculture (US) 1997-07-30 EP disclosed
EP-0785800-A4 US AGRICULTURE (US) 1997-07-30 EP disclosed
WO-1995016461-A1 PROBIOTIC FOR CONTROL OF $i(SALMONELLA) THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1995-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256367-A1 Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives ARSA, BMP2, BMP1 ALDH1A1 721/4885TSHR 3993/4885CYP2D6 1376/4885
US-20060004088-A1 Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same SOST, PTH1R, PTMS ALDH1A1 784/4885TSHR 4252/4885CYP2D6 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.